MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6506-1496-1506$20.00
Mol Pharmacol 65:1496-1506, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beljanski, V.
Right arrow Articles by Doetsch, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beljanski, V.
Right arrow Articles by Doetsch, P. W.

DNA Damage-Processing Pathways Involved in the Eukaryotic Cellular Response to Anticancer DNA Cross-Linking Drugs

Vladimir Beljanski, Luigi G. Marzilli, and Paul W. Doetsch

Departments of Chemistry (V.B., L.G.M.) and Biochemistry (P.W.D.) and Division of Cancer Biology and Department of Radiation Oncology (P.W.D.), Emory University, Atlanta, Georgia; and Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana (L.G.M.)

We used a panel of isogenic Saccharomyces cerevisiae strains compromised in several different DNA damage-processing pathways to assess in vivo processing of DNA adducts induced by four cross-linking anticancer drugs. By examining cytotoxicity profiles, cell cycle arrest patterns, and determining recombination and mutation frequencies, we found that cisplatin-, nitrogen mustard-, mitomycin-, and carmustine-induced DNA adducts in S. cerevisiae are processed by components of the nucleotide excision repair (NER), recombination repair (RR), and translesion synthesis (TLS) pathways, with substantially different contributions of each pathway for the drugs studied here. In contrast to previous studies that used single pathway-compromised strains to identify genes that mediate sensitivity to DNA cross-linking drugs, we used strains that were compromised in multiple pathways. By doing so, we were able to establish several functions that were previously unknown and interconnections between different DNA damage-processing pathways. To our surprise, we found that for cisplatin-induced cytotoxicity, TLS and RR contribute to survival to a significant extent. In the case of nitrogen mustard DNA adduct processing, equal involvement of two major pathways was established: one that requires functional RR and NER components and one that requires functional TLS and NER components. These data reveal the complexity of DNA cross-link processing that, in many cases, requires interactions of components from several different DNA damage-processing systems. We demonstrate the usefulness of yeast strains with multiple simultaneous defects in DNA damage-processing pathways for studying the modes of action of anticancer drugs.


Received November 12, 2003; accepted March 5, 2004

Address correspondence to: Paul W. Doetsch, Department of Biochemistry, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322. E-mail: medpwd{at}emory.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
B. J. Evison, F. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts
Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets
Mol. Pharmacol., July 1, 2008; 74(1): 184 - 194.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, L. Perez, J. C. Tercero, J. J. Vaquero, B. Albella, F. Gago, et al.
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Mol. Cancer Ther., May 1, 2008; 7(5): 1309 - 1318.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Liao, B. Hu, M. J. Arno, and B. Panaretou
Genomic Screening in Vivo Reveals the Role Played by Vacuolar H+ ATPase and Cytosolic Acidification in Sensitivity to DNA-Damaging Agents Such as Cisplatin
Mol. Pharmacol., February 1, 2007; 71(2): 416 - 425.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Yu, M. A. Mallon, W. Zhang, R. R. Freimuth, S. Marsh, M. A. Watson, P. J. Goodfellow, and H. L. McLeod
DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer
Clin. Cancer Res., September 1, 2006; 12(17): 5104 - 5111.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. B. Herrero, C. Martin-Castellanos, E. Marco, F. Gago, and S. Moreno
Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin
Cancer Res., August 15, 2006; 66(16): 8155 - 8162.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. J. Barber, T. A. Ward, J. A. Hartley, and P. J. McHugh
DNA Interstrand Cross-Link Repair in the Saccharomyces cerevisiae Cell Cycle: Overlapping Roles for PSO2 (SNM1) with MutS Factors and EXO1 during S Phase
Mol. Cell. Biol., March 15, 2005; 25(6): 2297 - 2309.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics